QTTB · Q32 Bio Inc.
$15.84
+0.55 (+3.60%)
At close · Aug 19
Going-concern doubt
— cleared Aug 5, 2026
The latest filing states the doubt was alleviated.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of June 30, 2026, the Company had an accumulated deficit of $221.5 million and cash and cash equivalents of $106.3 million. The Company expects that its cash and cash equivalents will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 5, 2026
Market Cap
$452.50M
Shares
29.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.84
Open$15.56
Day$15.25–15.93
52W close$1.66–21.38
Avg vol 30d1.9M
Short int3.0M · 10.1% float · 3.8d
Short vol69%
Last earningsAug 5, 2026
DataMar 2024–Aug 2026
Filing10-Q · Aug 5
Raw chart and full-history price indicators begin at the captured split on Mar 26, 2024; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+117%
above
Price vs 50-day avg
+10%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+233%
trailing
YTD return
+377%
this year
Relative strength
+221%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+34% holders QoQ · +27 funds added
Insider flow
Accumulating
Net +$30.0M over 90 days · 0% sells
Short interest
Rising
10.08% of float · ▲ +32.6% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 2-yr range
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
+137%
Y/Y
Free cash flow
$-33.5M
Balance sheet
$48.3M
net cash
Quant / Vol
risk profile
Volatility
174%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+117%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+34% holders QoQ · +27 funds added
Insider flow
Accumulating
Net +$30.0M over 90 days · 0% sells
Short interest
Rising
10.08% of float · ▲ +32.6% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $2
Now $16 · 72%
Range high $21
vs 200-day avg +117%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QTTB
this stock
Q32 Bio Inc.
|
$452.50M | +377.1% | -64.0% | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Mar 26, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QTTB | +3.1% | +5.0% | +232.8% | +1.0% | +377.1% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +3.5% | +2.1% | +221.2% | -1.9% | +364.3% |
Key facts
CIK
1661998
CUSIP
746964105
13F (30d)
74 filings
72 filers
Visit website
Investor relations